Cardiovascular events during carfilzomib therapy for relapsed myeloma: practical management aspects from two case studies

References

• Bladé J, Fernandez-Llama P, Bosch F, et al. Renal failure in multiple myeloma: presenting features and predictors of outcome in 94 patients from a single institution. Arch Intern Med. 1998;158(17):1889–1893. doi: 10.1001/archinte.158.17.1889
   PubMedGoogle Scholar
• Knudsen LM, Hjorth M, Hippe E. Renal failure in multiple myeloma: reversibility and impact on the prognosis. Nordic Myeloma Study Group. Eur J Haematol. 2000;65(3):175–181. doi: 10.1034/j.1600-0609.2000.90221.x
   PubMed Web of Science ®Google Scholar
• Sengul S, Li M, Batuman V. Myeloma kidney: toward its prevention – with new insights from in vitro and in vivo models of renal injury. J Nephrol. 2009;22(1):17–28.
   PubMed Web of Science ®Google Scholar
• Kistler KD, Kalman J, Sahni G, et al. Incidence and risk of cardiac events in patients with previously treated multiple myeloma versus matched patients without multiple myeloma: an observational, retrospective, cohort study. Clin Lymphoma Myeloma Leuk. 2017;17(2):89–96. doi: 10.1016/j.clml.2016.11.009
   PubMed Web of Science ®Google Scholar
• Suter TM, Ewer MS. Cancer drugs and the heart: importance and management. Eur Heart J. 2013;34(15):1102–1111. doi: 10.1093/eurheartj/ehs181
   PubMed Web of Science ®Google Scholar
• Revlimid Package Insert. Celgene Corporation, Summit, NJ, 02/2017. Available from: http://www.celgene.com/content/uploads/revlimid-pi.pdf.
   Google Scholar
• Honton B, Despas F, Dumonteil N, et al. Bortezomib and heart failure: case-report and review of the French Pharmacovigilance database. Fundam Clin Pharmacol. 2014;28(3):349–352. doi: 10.1111/fcp.12039
   PubMed Web of Science ®Google Scholar
• Tamargo J, Caballero R, Delpón E. Cancer chemotherapy and cardiac arrhythmias: a review. Drug Saf. 2015;38(2):129–152. doi: 10.1007/s40264-014-0258-4
   PubMed Web of Science ®Google Scholar
• Shah MH, Binkley P, Chan K, et al. Cardiotoxicity of histone deacetylase inhibitor depsipeptide in patients with metastatic neuroendocrine tumors. Clin Cancer Res. 2006;12(13):3997–4003. doi: 10.1158/1078-0432.CCR-05-2689
   PubMed Web of Science ®Google Scholar
• Foley PW, Hamilton MS, Leyva F. Myocardial scarring following chemotherapy for multiple myeloma detected using late gadolinium hyperenhancement cardiovascular magnetic resonance. J Cardiovasc Med (Hagerstown). 2010;11(5):386–388. doi: 10.2459/JCM.0b013e32832f3ff2
   PubMed Web of Science ®Google Scholar
• Aota Y, Gotoh A, Hanyu N, et al. Bortezomib-associated acute congestive heart failure in a patient with multiple myeloma. Rinsho Ketsueki. 2015;56(1):44–47.
   PubMedGoogle Scholar
• Gupta A, Pandey A, Sethi S. Bortezomib-induced congestive cardiac failure in a patient with multiple myeloma. Cardiovasc Toxicol. 2012;12(2):184–187. doi: 10.1007/s12012-011-9146-7
   PubMed Web of Science ®Google Scholar
• Dasanu CA. Complete heart block secondary to bortezomib use in multiple myeloma. J Oncol Pharm Pract. 2011;17(3):282–284. doi: 10.1177/1078155210367839
   PubMedGoogle Scholar
• Takamatsu H, Yamashita T, Kotani T, et al. Ischemic heart disease associated with bortezomib treatment combined with dexamethasone in a patient with multiple myeloma. Int J Hematol. 2010;91(5):903–906. doi: 10.1007/s12185-010-0586-9
   PubMed Web of Science ®Google Scholar
• Lee WS, Kim DH, Shin SH, et al. Complete atrioventricular block secondary to bortezomib use in multiple myeloma. Yonsei Med J. 2011;52(1):196–198. doi: 10.3349/ymj.2011.52.1.196
   PubMed Web of Science ®Google Scholar
• Meseeha MG, Kolade VO, Attia MN. Partially reversible bortezomib-induced cardiotoxicity: an unusual cause of acute cardiomyopathy. J Community Hosp Intern Med Perspect. 2015;5(6):28982. doi: 10.3402/jchimp.v5.28982
   PubMed Web of Science ®Google Scholar
• Bockorny M, Chakravarty S, Schulman P, et al. Severe heart failure after bortezomib treatment in a patient with multiple myeloma: a case report and review of the literature. Acta Haematol. 2012;128(4):244–247. doi: 10.1159/000340050
   PubMed Web of Science ®Google Scholar
• Subedi A, Sharma LR, Shah BK. Bortezomib-induced acute congestive heart failure: a case report and review of literature. Ann Hematol. 2014;93(10):1797–1799. doi: 10.1007/s00277-014-2026-z
   PubMed Web of Science ®Google Scholar
• Diwadkar S, Patel AA, Fradley MG. Bortezomib-induced complete heart block and myocardial scar: the potential role of cardiac biomarkers in monitoring cardiotoxicity. Case Rep Cardiol. 2016;2016:3456287.
   PubMedGoogle Scholar
• Scott K, Hayden PJ, Will A, et al. Bortezomib for the treatment of multiple myeloma. Cochrane Database Syst Rev. 2016;4:CD010816.
   PubMedGoogle Scholar
• Xiao Y, Yin J, Wei J, et al. Incidence and risk of cardiotoxicity associated with bortezomib in the treatment of cancer: a systematic review and meta-analysis. PLoS ONE. 2014;9(1):e87671. doi: 10.1371/journal.pone.0087671
   PubMed Web of Science ®Google Scholar
• Siegel D, Martin T, Nooka A, et al. Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies. Haematologica. 2013;98(11):1753–1761. doi: 10.3324/haematol.2013.089334
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Moreau P, Palumbo A, et al. Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. Lancet Oncol. 2016;17(1):27–38. doi: 10.1016/S1470-2045(15)00464-7
   PubMed Web of Science ®Google Scholar
• Chen JH, Lenihan DJ, Phillips SE, et al. Risk factors for cardiac toxicities associated with proteasome inhibitor chemotherapy during treatment of multiple myeloma. Blood. 2015;126: 5363.
   Web of Science ®Google Scholar
• Quach H, White D, Spencer A, et al. An open-label, single-arm, phase 1 study of the pharmacokinetics (PK) and safety of carfilzomib in patients with relapsed multiple myeloma and end-stage renal disease (ESRD). Blood. 2016;128: 3318.
   Google Scholar
• Bui AL, Horwich TB, Fonarow GC. Epidemiology and risk profile of heart failure. Nat Rev Cardiol. 2011;8(1):30–41. doi: 10.1038/nrcardio.2010.165
   PubMed Web of Science ®Google Scholar
• KYPROLIS® (carfilzomib) prescribing information. South San Francisco, CA: Onyx Pharmaceuticals, Inc; 11/2016 Available from: http://pi.amgen.com/~/media/amgen/repositorysites/pi-amgen-com/kyprolis/kyprolis_pi.ashx. Accessed May 16 2017.
   Google Scholar
• Mikhael J. Management of carfilzomib-associated cardiac adverse events. Clin Lymphoma Myeloma Leuk. 2016;16(5):241–245. doi: 10.1016/j.clml.2016.01.008
   PubMed Web of Science ®Google Scholar
• Russel SD, Lyon A, Lenihan D, et al. Serial echocardiographic assessment of patients (pts) with relapsed multiple myeloma (RMM) receiving carfilzomib and dexamethasone (Kd) vs bortezomib and dexamethasone (Vd): a substudy of the phase 3 ENDEAVOR trial (NCT01568866). Blood. 2015;126: 4250.
   Web of Science ®Google Scholar
• Stewart AK, Rajkumar SV, Dimopoulos MA, et al. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med. 2015;372(2):142–152. doi: 10.1056/NEJMoa1411321
   PubMed Web of Science ®Google Scholar